1Cavasin M A, Rhaleb N E, Yang X P, et al. Prolyl oligopeptidase is involved in release of the antifibrotic peptide Ac - SDKP . Hypertension, 2004, 43(5) : 1140
2Bogden A E, Moreau J P, Gamba - Vitalo C, et al. Goralatide (AcSD-KP), a negative growth regulator, protects the stem cell compartment during chemotherapy, enhancing the myelopoietic response to GM -CSF. Int J Cancer, 1998, 76 : 38
4Jackson J D, Ozerol E, Yan Y, et al. Activity of acetyl - Ser - Asp -Lys - Pro(AcSDKP) on human hematopoietic progenitor cells in short -term and long - term bone marrow cultures . J Hematother Stem Cell Res, 2000, 9 : 489
6Watanabe T, Brown G S, Kelsey L S, et al. In vivo protective effects of tetrapeptide AcSDKP, with or without granulocytecolony - stimulation factor, on murine progenitor cells after sublethal irradiation . Exp Hematol, 1996, 24 : 713
7Wierenge P K, Brenner M K, Konings AWT. Enhanced selectivity of hyperthermic purging of human progenitor cells using Goralatide, an inhibitor of cell cycle progression . Bone Marrow Transplant, 1998,21 :73
8Masse A, Ramirez L H, Bindoula G, et al. The tetrapeptide acetyl -N- Ser - Asp - Lys - Pro ( Goralatide ) protects from doxorubicin - induced toxicity: improvement in mice survival and protection of bone marrow stem cells and progenitors . Blood, 1998, 91(2) : 441
9Suzuki A, Aizawa S, Araki S, et al. Enhanced engraftment of intravenously transplanted hematopoietic stem cells into bone marrow of irradiated mice treated with AcSDKP . Exp Hematol, 1998, 26(1 ) : 79
10Li X M, Ezan E, Bindoula G, et al. Chronopharmacologic aspects of continuous AcSDKP infusion in mice. Exp Hematol, 1999, 27(1) :19
2Suzuki A, Aizawa S, Araki S, et al. Enhanced engraftment of intravenously transplanted hematopoietic stem cells into bone marrow of irradiated mice treated with AcSDKP [J].Exp Hematol, 1998, 26(1):79-83.
3Wierenga PK, Brenner MK, Konings AW. Enhanced selectivity of hyperthermic purging of human progenitor cells using goralatide, an inhibitor of cell cycle progression[J]. Bone Marrow Transplant, 1998, 21(1):73-78.
4Rousseau-Plasse A, Wdzieczak-Bakala J, Lenfant M, et al.Lisinopril, an angiotensin Ⅰ-converting enzyme inhibitor,prevents entry of murine hematopoietic stem cells into the cell cycle after irradiationin vivo[J]. Exp Hematol, 1998,26(11): 1074 - 1079.
5Paukovits WR, Paukovits JB, Moser MH, et al. Activated granulocytes oxidize the endogenous stem cell inhibitory peptide pGlu-Glu-Asp-Cys-Lys (pEEDCK) to the stimulatory dimer: a redox-mediated mechanism for demand-induced hematopoietic regulation[J]. Exp Hematol, 1998, 26(9):851 - 858.
6Paukovits JB, Rutter R, Ganglberger E, et al. The hemoregulatory peptide pEEDCK may inhibit stem cell proliferation via hydropathic binding to antisense sequence motifs in interleukin-11 and other growth factors [J]. Mol Pharmacol, 1999, 56(4) :665 - 674.
7Cheviron N, Grillon C, Carlier MF, et al. The antiproliferative activity of the tetrapeptide acetyl- N-Ser-Asp-Lys-Pro,an inhibitor of haematopoietic stem cell proliferation, is not mediated by a thymosin beta 4-like effect on actin assembly [J]. Cell Prolif, 1996, 29(8):437-446.
8Huang WQ, Wang QR. Bone marrow endothelial cells secrete thymosin beta 4 and AcSDKP [J]. Exp Hematol,2001, 29(1): 12 - 18.
9Rameshwar P, Gascon P. Hematopoietic modulation by the tachykinins[J]. Acta Haematol , 1997, 98(2) :59 - 64.
10Gascon P, Qian J, Joshi DD, et al. Effects of preprotachykinin-Ⅰ peptides on hematopoietic homeostasis. A role for bone marrow endopeptidases [J]. Ann NY Acad Sci,2000, 917:416-423.
